![](/fileadmin/_processed_/csm_tubulis_linker_ADC_web_bccd46dac0.jpg)
Tubulis from Munich doses first Patient with own ADC linker technology
Tubulis, based in Martinsried near Munich, announced today that the first patient has been treated in its first Phase 1/2a...
![](/fileadmin/_processed_/csm_Microglia_and_neurons_c__Gary_Shaw_ed89bb0973.jpg)
Researchers identify blockers of CNS effects of PD1 cancer therapy
In mouse models, a group headed by Marco Prinz from University Freiburg demonstrated that adverse side effects of immune cancer therapies with PD1...
![](/fileadmin/_processed_/csm_SFactory01_Launch_044ec847f4.png)
Solar Foods starts Factory01
Following market authorisation in Singapore two years ago, the Finnish company Solar Foods Oy and the Japanese food giant Ajinomoto Group want to...
![](/fileadmin/_processed_/csm_Adrenomed_cf30735df8.png)
Shock: Adrenomed AG gets FDA fast track designation
After Adrenomed AG has demonstrated that its septic shock treatment led to a 60% reduction in relative 28-day mortality vs. placebo in a stratified...
![](/fileadmin/_processed_/csm_AC_Immune-Pipeline_0531719e36.png)
AC Immune and Takeda ink US$2.1bn biobucks deal
Under the US$2.1bn biobucks deal, Pharma giant Takeda gets the globally exclusive right to licence AC Immune SA's active immunisation therapy...
![](/fileadmin/_processed_/csm_Fundus_-_diabetic_retinopathy_c83d88301e.png)
MSD grabs Eyebiotech Ltd for US$1.3bn upfront
With the strategic acquisition,which has been unanimously approved by the EyeBio Board of Directors, MSD will take over Eyebiotech's clinical...
![](/fileadmin/_processed_/csm_Cardior_43-Edit_copy_7afe8be7f7.png)
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....